Vaccine composition

US7220415B1 · kind B1 · utility

Assignee

• Gunnar Lindahl · SE

Inventors

• Margaretha Stalhammar-Carlemalm · Lund, SE
• Thomas Areschoug · Lund, SE
• Charlotte Larsson · Lund, SE
• Gunnar Lindahl · Lund, SE

Key dates

• Filing date: May 5, 2000
• Grant date: May 22, 2007
• Expiry date: May 5, 2020

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K39/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A polypeptide is described herein which comprises (a) the sequence of SEQ ID No. 2, (b) a variant of (a) which is capable of generating a protective immune response to S. pyogenes, or (c) a fragment of (a) or (b) of at least 6 amino acids in length which is capable of generating a protective immune response to S. pyogenes, in the manufacture of medicament for use as a vaccine against S. pyogenes. A pharmaceutical composition for use in vaccinating against S. pyogenes or Group B streptococcus comprises a polypeptide which comprises: (A) the amino acid sequence of SEQ ID No. 2, (B) a variant of (A) which is capable of conferring protective immunity to S. pyogenes or Group B streptococcus, or (C) a fragment of (A) or (B) of at least 6 amino acids in length which is capable of conferring protective immunity to S. pyogenes or Group B streptococcus.